dacarbazine and cep 8983

dacarbazine has been researched along with cep 8983 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ator, M; Chang, H; Deibold, J; Grobelny, J; Hudkins, R; Husten, J; McGann, N; Miknyoczki, S; Parchment, R; Pritchard, S; Ruggeri, B; Worrell, C; Zulli, A	1
Aissat-Daudigny, L; Brown, PD; Cambois, A; Campone, M; Moachon, G; Plummer, R; Stephens, P	1

Trials

1 trial(s) available for dacarbazine and cep 8983

Article	Year
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalimides; Poly(ADP-ribose) Polymerase Inhibitors; Prodrugs; Prognosis; Temozolomide; Tissue Distribution; Young Adult	2014

Article

Year

Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.

Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:2

Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalimides; Poly(ADP-ribose) Polymerase Inhibitors; Prodrugs; Prognosis; Temozolomide; Tissue Distribution; Young Adult

2014

Other Studies

1 other study(ies) available for dacarbazine and cep 8983

Article	Year
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Molecular cancer therapeutics, 2007, Volume: 6, Issue:8 Topics: Animals; Antineoplastic Agents; Camptothecin; Carbazoles; Cell Death; Cell Line, Tumor; Cell Proliferation; Comet Assay; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase; Humans; Irinotecan; Mice; Phthalimides; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide; Xenograft Model Antitumor Assays	2007

Article

Year

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.

Molecular cancer therapeutics, 2007, Volume: 6, Issue:8

Topics: Animals; Antineoplastic Agents; Camptothecin; Carbazoles; Cell Death; Cell Line, Tumor; Cell Proliferation; Comet Assay; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase; Humans; Irinotecan; Mice; Phthalimides; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide; Xenograft Model Antitumor Assays

2007